70 related articles for article (PubMed ID: 36367559)
1. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
[TBL] [Abstract][Full Text] [Related]
2. How I treat secondary CNS involvement by aggressive lymphomas.
Alderuccio JP; Nayak L; Cwynarski K
Blood; 2023 Nov; 142(21):1771-1783. PubMed ID: 37702537
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate for elderly patients with primary CNS lymphoma.
Zhu JJ; Gerstner ER; Engler DA; Mrugala MM; Nugent W; Nierenberg K; Hochberg FH; Betensky RA; Batchelor TT
Neuro Oncol; 2009 Apr; 11(2):211-5. PubMed ID: 18757775
[TBL] [Abstract][Full Text] [Related]
4. [Clinical study of 15 cases of primary non-immunodeficient central nervous system lymphoma in children].
Gao HX; Zhang NN; Zhou CJ; Jin L; Yang J; Huang S; Zhang M; Li N; Zhang YH; Duan YL
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):190-194. PubMed ID: 38604797
[TBL] [Abstract][Full Text] [Related]
5. Different patterns of failure in two treatment regimens for primary central nervous system lymphoma, a retrospective analysis of 124 cases in Taiwan.
Chuang CH; Kuo MC; Chang H; Wu JH; Hung YS; Ou CW; Lin TL; Su YJ; Ong YC; Shih LY; Kao HW
Clin Exp Med; 2023 Dec; 23(8):5327-5336. PubMed ID: 37679606
[TBL] [Abstract][Full Text] [Related]
6. Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma.
Motomura Y; Yoshifuji K; Tachibana T; Takase H; Arai A; Tanaka K; Okada K; Nogami A; Umezawa Y; Sakashita C; Yamamoto M; Mori T; Nagao T
Br J Haematol; 2024 Apr; 204(4):1279-1287. PubMed ID: 38131400
[TBL] [Abstract][Full Text] [Related]
7. Central Nervous System Lymphoma.
Schaff L
Continuum (Minneap Minn); 2023 Dec; 29(6):1710-1726. PubMed ID: 38085895
[TBL] [Abstract][Full Text] [Related]
8. Central Nervous System Relapse in T and NK cell Lymphomas.
Taranto EP; Barta SK; Bhansali RS
Curr Hematol Malig Rep; 2023 Dec; 18(6):243-251. PubMed ID: 37620711
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate and zanubrutinib combination therapy for primary central nervous system lymphoma.
Yadav BS
World J Clin Oncol; 2024 Mar; 15(3):371-374. PubMed ID: 38576595
[TBL] [Abstract][Full Text] [Related]
10. Diffuse large B-cell lymphoma with contemporary involvement of central and peripheral nervous system: A case report and literature review.
Tang C; Jiang P; Tang J; Liao J; Zeng Q
Heliyon; 2024 Apr; 10(7):e28552. PubMed ID: 38560176
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma.
Fan N; Zhang L; Xu X; Chen B; Zhu C; Li P; Chen Z; Ding T; Ma Y; Yuan Y; Lin Z
Oncotarget; 2017 Aug; 8(32):53701-53713. PubMed ID: 28881844
[TBL] [Abstract][Full Text] [Related]
12. Primary central nervous system lymphoblastic B cell lymphoma located at cerebellum in a child: A case report and literature review.
Yang X; Duan Y; Zhou C; Jin L; Zhang N; Huang S; Zhang M; Yang J; Zhang Y
Pediatr Investig; 2021 Dec; 5(4):318-322. PubMed ID: 34938975
[TBL] [Abstract][Full Text] [Related]
13. Could Cerebral Inflammatory Lesions be the Cellular Origin of Primary Central Nervous System Lymphoma?
Ma J; Wang H; Chen T; Bai H; Zhang J; Yu X
J Craniofac Surg; 2024 May; ():. PubMed ID: 38709059
[TBL] [Abstract][Full Text] [Related]
14. Acute Presentation of Primary CNS Lymphoma Mimicking Toxoplasma in HIV Infection.
Acharya I; DeBoer SR; Bhansali D
J Community Hosp Intern Med Perspect; 2023; 13(6):17-23. PubMed ID: 38596565
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: a RANO review.
Nayak L; Bettegowda C; Scherer F; Galldiks N; Ahluwalia M; Baraniskin A; von Baumgarten L; Bromberg JEC; Ferreri AJM; Grommes C; Hoang-Xuan K; Kühn J; Rubenstein JL; Rudà R; Weller M; Chang SM; van den Bent MJ; Wen PY; Soffietti R
Neuro Oncol; 2024 Apr; ():. PubMed ID: 38598668
[TBL] [Abstract][Full Text] [Related]
16. Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.
Godfrey JK; Gao L; Shouse G; Song JY; Pak S; Lee B; Chen BT; Kallam A; Baird JH; Marcucci G; Ghoda LY; Vauleon S; Danilov AV; Herrera AF; Kwak LW; Budde LE
Blood; 2024 Mar; ():. PubMed ID: 38484137
[TBL] [Abstract][Full Text] [Related]
17. Primary central nervous system lymphoma.
Ferreri AJM; Calimeri T; Cwynarski K; Dietrich J; Grommes C; Hoang-Xuan K; Hu LS; Illerhaus G; Nayak L; Ponzoni M; Batchelor TT
Nat Rev Dis Primers; 2023 Jun; 9(1):29. PubMed ID: 37322012
[TBL] [Abstract][Full Text] [Related]
18. CNS prophylaxis in aggressive B-cell lymphoma.
Wilson MR; Bobillo S; Cwynarski K
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):138-145. PubMed ID: 36485105
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
